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The purpose of this study was to determine the deep sequencing and analytic conditions needed to detect fetal subchromosome abnor-
malities across the genome from a maternal blood sample. Cell-free (cf) DNA was isolated from the plasma of 11 pregnant women
carrying fetuses with subchromosomal duplications and deletions, translocations, mosaicism, and trisomy 20 diagnosed by metaphase
karyotype. Massively parallel sequencing (MPS) was performed with 25-mer tags at approximately 109 tags per sample and mapped to
reference human genome assembly hg19. Tags were counted and normalized to fixed genome bin sizes of 1Mb or 100 kb to detect statis-
tically distinct copy-number changes compared to the reference. All seven cases of microdeletions, duplications, translocations, and the
trisomy 20 were detected blindly by MPS, including a microdeletion as small as 300 kb. In two of these cases in which the metaphase
karyotype showed additional material of unknown origin, MPS identified both the translocation breakpoint and the chromosomal
origin of the additional material. In the four mosaic cases, the subchromosomal abnormality was not demonstrated by MPS. This
work shows that in nonmosaic cases, it is possible to obtain a fetal molecular karyotype by MPS of maternal plasma cfDNA that is equiv-
alent to a chromosome microarray and in some cases is better than a metaphase karyotype. This approach combines the advantage of
enhanced fetal genomic resolution with the improved safety of a noninvasive maternal blood test.Introduction
Two major recent advances in prenatal diagnosis, chromo-
some microarrays (CMA) and noninvasive prenatal testing
(NIPT) via sequencing of maternal plasma cell-free DNA,
have already translated to clinical care and are changing
widely accepted clinical paradigms.1 According to the
recommendations of several expert groups, CMAs have
replaced the standard metaphase karyotype in the post-
natal assessment of individuals with developmental delay,
intellectual disability, congenital anomalies, and autism.2
Discussion is ongoing regarding the role of CMAs in
prenatal diagnosis.3,4 Recently, an NIH-sponsored clinical
trial investigating the accuracy of fetal diagnosis by com-
paring metaphase karyotype to CMA was completed.5
The results showed an increase in the detection of clini-
cally significant copy-number changes even when the
metaphase karyotype was apparently normal at conven-
tional levels of resolution. To use CMAs, however, an inva-
sive procedure such as amniocentesis or chorionic villus
sampling (CVS) must be performed to obtain a source of
fetal genomic DNA. These procedures carry small but
well-validated rates of spontaneous pregnancy loss and
they can be performed only by obstetricians who have
specialized training.
At the same time, major progress has been achieved in
the ability to noninvasively detect whole-chromosome
aneuploidy by massively parallel sequencing (MPS) of
maternal plasma cell-free (cf) DNA that includes fetal
cfDNA originating from the placenta.1 In two studies pub-
lished in 2007, molecular counting utilizing digital PCR
indicated that it was possible to determine relative over-1Verinata Health, Inc., Redwood City, CA 94063, USA; 2Mother Infant Research
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The Americor underrepresentation of specific chromosomes, thus
inferring the presence of fetal aneuploidy from a maternal
plasma sample.6,7 A year later the counting approach tran-
sitioned to MPS,8,9 rapidly followed by multiple indepen-
dent clinical trials that assessed the accuracy of NIPT for
the detection of trisomies 21, 18, and 13.1 The success of
these trials has led to the clinical introduction of MPS as
an alternative to invasive procedures for women carrying
fetuses at high risk for whole-chromosome aneu-
ploidies.10
An increasing body of literature has also documented
the feasibility of detection of autosomal subchromosome
fetal abnormalities by MPS of maternal plasma cfDNA. In
an unblinded study, a 4.2 megabase (Mb) paternally in-
herited deletion of chromosome 12p11.22 to 12p12.1
was found in a maternal sample taken at 35 weeks of gesta-
tion.11 In two cases of fetuses previously diagnosed with
DiGeorge syndrome, sequencing of maternal plasma
demonstrated the presence of the pathognomonic 22q11
deletion.12 In blinded studies, our laboratory detected the
presence of a small deletion in chromosome 11q21–2313
and a duplication of 6q.14
The success of MPS to detect both whole and subchro-
mosome fetal copy number variation depends on the
percentage of fetal DNA in the maternal blood sample,
which is referred to as the relative fetal fraction (ff).
Although early literature suggested that the characteristic
ff averaged only 5%–6%,15 subsequent MPS studies have
determined that ffs of between 10% and 15% are more
typical.16,17 The higher ffs make it more likely that sub-
chromosomal fetal abnormalities can be determined with
these methods. They also provide the opportunity toInstitute at Tufts Medical Center and Tufts University School of Medicine,
y of Human Genetics.
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Table 1. Karyotypes of Maternal Plasma Samples Analyzed by MPS
Sample ID Specimen Procedure Karyotype
AL1893 chorionic villi metaphase and 20q12 FISH 47,XX,þ20
BE3096 cultured villi metaphase, 6q12, 6q16.3 FISH,
and microarray
arr 6q12q16.3(64,075,795-101,594,105)x3,
6q16.3(102,176,578-102,827,691)x3
BF3404 chorionic villi metaphase 46,XY,del(7)(q36.1)
AK1604 amniocytes metaphase and 22q FISH 46,XX,del(8)(p23.1p23.2)
BE3236 chorionic villi metaphase and Chr 15 FISH 45,XX,-15,der(21)t(15;21)(q15;p11.2)
AF1019 amniocytes metaphase 46,XY,add(10)(q26)
BC2659 amniocytes metaphase 46,XX,add(X)(p22.1)
AL1873 amniocytes metaphase and FISH 46,XY or 46,XY,add(15)(p11.2)
BE3129 amniocytes metaphase mos 46,XY,þi(20)(q10)[8]/46,XY[17]
BG3701 chorionic villi metaphase and FISH 47,XY,þder(14 or 22)[10]/46,XY[10]
AH1200 chorionic villi metaphase 47,XXþmar[12]/46,XX[8]
The last four samples have mosaic karyotypes.confirm observed structural variations and avoid false-
positive test results.
The purpose of the current study was to determine the
deep sequencing and analytic conditions needed to nonin-
vasively detect fetal subchromosome abnormalities across
the genome. Our goal was to create the equivalent of a
CMA that could be applied to a maternal blood sample.
If successful, this would combine the advantages of the
greater genomic resolution provided by CMAs with the
increased safety of performing a blood test instead of an
invasive procedure. Here we show that it is possible to
detect fetal subchromosome abnormalities at a resolution
of 100 kb across the genome, validating the concept of
a noninvasive molecular karyotype of the fetus that could
have clinical utility in the near future.Material and Methods
Sample Preparation and Sequencing
Artificial Mixtures
To determine the depth of sequencing needed to detect fetal sub-
chromosome abnormalities and to assess the effect of the relative
ff of cfDNA present in the sample, we created artificial mixtures of
5% and 10% sheared genomic DNA by using paired mother and
child DNAs obtained from the Coriell Institute for Medical
Research (Camden, NJ). All children were males with karyotypes
previously determined by metaphase cytogenetic analysis. The
karyotypes of the four paired samples are shown in Table S1
available online. The children’s chromosome abnormalities were
selected to represent different clinical scenarios, such as (1)
whole-chromosome aneuploidy (family 2139), (2) subchromoso-
mal deletion (family 1313), (3) mosaic subchromosomal copy-
number change (family 2877, with an additional inherited
deletion), and (4) a derivative chromosome that contains a sub-
chromosomal duplication (family 1925).
The genomic DNA samples were sheared to a size of ~200 bp
via the Covaris S2 sonicator (Covaris, Woburn, MA) according to
the manufacturer’s recommended protocols. DNA fragments168 The American Journal of Human Genetics 92, 167–176, Februarysmaller than 100 bp were removed with AmPure XP beads (Beck-
man Coulter Genomics, Danvers, MA). Sequencing libraries were
generated with TruSeq v1 Sample Preparation kits (Illumina, San
Diego, CA) from sheared DNA mixtures consisting of maternal
DNAonly andmaternalþ childDNAmixtures at 5%and10%w/w.
Samples were sequenced with single-ended 36 base pair (bp) reads
on the Illumina HiSeq 2000 instrument via TruSeq v3 chemistry.
Each sample was sequenced on four lanes of a flow cell, resulting
in 400 3 106 to 750 3 106 sequence tags per sample.
Maternal Plasma Samples
The Maternal Blood Is Source to Accurately Diagnose Fetal
Aneuploidy (MELISSA) trial was a registered clinical trial
(NCT01122524) that recruited high-risk pregnant subjects and
plasma samples from 60 different centers in the United States,
along with the corresponding metaphase karyotype results from
an invasive prenatal diagnostic procedure. Each of the medical
centers conducted the study with approval by their local institu-
tional review boards. Written informed consent was obtained
from each study participant. The study was designed to prospec-
tively determine the accuracy of MPS to detect whole-chromo-
some fetal aneuploidy. During this trial, all samples with any
abnormal karyotype were included to emulate the real clinical
scenarios in which the fetal karyotype is not known at the time
of sample acquisition. The results of this study have been previ-
ously published.14 After completion of the MELISSA trial, the
study database was assessed to identify ten samples that had
complex karyotypes, including subchromosome abnormalities,
material of unknown origin, or a marker chromosome (Table 1);
we also added one MELISSA study sample with trisomy 20 as
a control of performance in detection of whole-chromosome
aneuploidy. The karyotypes were performed for standard clinical
indications and reflected local protocols. For example, some fetal
samples were analyzed with CMAs and some had metaphase anal-
ysis with or without FISH studies.
In the MELISSA study, libraries were sequenced with single-
end reads of 36 bp with 6 samples in a lane on an Illumina
HiSeq 2000 with TruSeq v2.5 chemistry. In the present study,
the previously generated MELISSA libraries were resequenced
with TruSeq v3 chemistry on an Illumina HiSeq 2000 with
single-end reads of 25 bp. In this study, each of the 11 maternal7, 2013
samples was sequenced with an entire flow cell, resulting in 6003
106 to 1.3 3 109 sequence tags per sample. All sequencing was
performed in the Verinata Health research laboratory (Redwood
City, CA) by research laboratory personnel who were blinded to
the fetal karyotype.
Normalization and Analysis
Sequence reads were aligned to the human genome assembly hg19
obtained from the UCSC database. Alignments were carried out
utilizing the Bowtie short read aligner (version 0.12.5), allowing
for up to two base mismatches during alignment. Only reads
that unambiguously mapped to a single genomic location were
included. Genomic sites at which reads mapped were counted as
tags. Regions on the Y chromosome at which sequence tags
from male and female samples mapped without any discrimina-
tion were excluded from the analysis (specifically, from base 0 to
base 2 3 106; base 10 3 106 to base 13 3 106; and base 23 3 106
to the end of chromosome Y).
The genome was then further divided into contiguous 1 Mb and
100 kb bins and, for each sample, tags from both the positive and
negative strand were assigned to individual bins for further anal-
ysis. The GC percentage of each bin was determined and bins
were ranked by GC percentage across the entire genome. Each
bin was individually normalized by calculating the ratio of tags
within a bin to the sum of the number of tags in bins with the
nearest GC percentages by
BRVij ¼ TagsijP
Tagskm
; (Equation 1)
where BRVij is the bin ratio value for the j
th bin of chromosome i
and Tagsij is the number of tags in the j
th bin of chromosome i.
The sum runs over the 10 bins for the 1 Mb data and 40 bins
for the 100 kb data for bins (km) with the nearest GC percentage
to bin ij.
In order to detect any subchromosomal differences, we exam-
ined each of the BRVs for deviations from the median values
measured across multiple samples. The medians were determined
from the four maternal only DNAs (Table S1) for the artificial
samples and from the 11 maternal plasma samples (Table 1) for
the clinical samples and were robust to individual subchromoso-
mal variants that might have been present in any one of the
samples. Median absolute deviations (MADs) were calculated for
each bin based on the medians and adjusted assuming a normal
distribution for the number of tags in each bin. The MADs were
adjusted (aMADs) assuming that the BRVs followed a normal
distribution (i.e., MAD was multiplied by 1.4826) and were
utilized to calculate a z score for each bin:
zij ¼

BRVij  BRVMedianij

aMADij
: (Equation 2)
We expected zij to be approximately zero to 53 for regions
(i.e., ~99.8% of values in the normal distribution) without any
copy-number variants (CNVs) and significantly greater than 3
when fetal CNVs were present.
The zij values can be utilized to determine the relative ff
present in the cfDNA. The value can then be compared to an
independent measurement of ff to validate copy number
detection, or suggest the presence of mosaicism. For a bin ratio
containing a copy-number change from normal, the BRVij will
increase (in the case of a duplication) or decrease (in the case of
a deletion):The AmericBRVij ¼

15
ffn
2

BRVMedianij : (Equation 3)In this equation, ffn is the fetal fraction for sample n. If we define
the coefficient of variation for each bin, CVij as
CVij ¼ aMADij
BRVMedianij
; (Equation 4)
then
ffn ¼ abs

2zijCVij

(Equation 5)
can be used to calculate ffn for sample n from zij values when
a CNV is present.
Detection and Classification of CNVs
Detection of a subchromosomal abnormality was a three-step
process for classifying specific regions as having a CNV
present. In step 1, we identified zij values from the 1 Mb bins
that exceeded 54. The zij 5 4 thresholds are indicated in each
figure by a dashed horizontal line. The ff was then calculated by
applying Equation 5 and bins that had a ff of less than 4% were
eliminated. For the samples from pregnant women carrying
male fetuses, the ff was also calculated with all of the bins in
chromosome X. This value was compared to the result obtained
for putative copy number changes to validate a copy-number
change or suggest a mosaic result. Finally, in cases in which only
a single 1 Mb bin met the above criteria, we examined the 100
kb bins data and required that at least 2 bins within a contiguous
group of 4 indicated a zij value that exceeded þ4 or 4 before
classifying a sample as having a CNV present. All three
criteria had to be fulfilled to classify the CNV. For example, indi-
vidual data points that only had a z score of greater than or less
than 4 but did not meet the additional criteria were not classified
as CNVs.Results
Artificial Mixtures
Whole-Chromosome Aneuploidy of Chromosome 21
Figure S1 shows the chromosome 21 z21j values (1Mb bins)
for an artificial mixture of family 2139 with 10% of the
son’s DNA (T21) mixed with the mother’s DNA. In chro-
mosome 21, there are approximately 38 Mb (35 Mb in
the q arm) that contain unique reference genome
sequence in hg19. All of the chromosome 21 tags mapped
to this region. With the exception of the first 4 Mb,
Figure S1 shows an overrepresentation of a 34 Mb region
of chromosome 21 in the 10% mixture, as would be
expected with a full-chromosome aneuploidy. With
Equation 5 to calculate the ff from the average z21j values
of the amplified regions, we obtained ffs of 7.0% and
12.7% for the 5% and 10% mixtures, respectively. Calcu-
lating the ff average with chromosome X zXj values, we
obtained ffs of 4.2% and 9.0% for the 5% and 10%
mixtures, respectively.
Subchromosomal Deletion of Chromosome 7
We next tested the method on Family 1313, in which the
son has a subchromosomal deletion of chromosome 7.
Figure 1 shows the chromosome 7 z7j values (1 Mb bins)
for the maternal sample mixed with 10% of her son’san Journal of Human Genetics 92, 167–176, February 7, 2013 169
Figure 1. Family 1313 z7j 1 Mb Bin Results for Chr 7
The data show the 0% (solid circles) and 10% (empty circles)
mixtures of the affected son’s DNA mixed with the mother’s
DNA. The red circle highlights bin 98. The figure shows a 20 Mb
deletion on Chr 7 in the DNA mixture, covering the region
between 38 Mb and 58 Mb of the chromosome. Additionally,
a potential maternal copy number increase, not shared by the
son, is seen at 98 Mb.
Figure 2. Family 2877 zij 1 Mb Bin Results
The data show results for Chr 11 (A) and Chr 15 (B) with 0% (solid
circles) and 10% (empty circles) mixture of the affected son’s DNA
mixed with the mother’s DNA.
(A) An 8 Mb deletion for Chr 11 in both mother-only and the
mixed DNAs, covering the region from 41 Mb to 49 Mb of Chr
11; this deletion is shared by mother and son.
(B) The son-specific CNV in Chr 15 from 27 Mb to 66 Mb.DNA. A deletion was observed beginning at bin 38
and continuing to bin 58. This reflects the approximately
20 Mb deletion documented in the metaphase karyotype.
We calculated ffs of 6.1% and 10.5% for the 5% and 10%
mixtures, respectively, for this sample. Calculating the ff
average with chromosome X zXj values, we obtained ffs
of 5.9% and 10.4%, respectively. Interestingly, in this
sample we also noted what appeared to be a duplication
in the maternal sample at bin 98 of chromosome 7 (red
circle in Figure 1), which did not appear in the son, i.e.,
was not inherited. If this duplication was maternally in-
herited, we would not expect the z7j value to decrease
in the mixture. As seen in Figure 1, the value of z7j is
lower for the 10% mixture compared to the pure
maternal sample.
Mosaic Duplication of Chromosome 15
In Family 2877, the maternal sample has a deletion in
chromosome 11 that was inherited by the son. In addition,
the son has a duplication in chromosome 15 that was not
maternally inherited and is part of a mosaic karyotype in
which the majority of cells are normal (Table S1). Figure 2
shows both the chromosome 11 and chromosome 15 zij
values for the 1 Mb bins in the mixture with 10% of the
son’s DNA. As expected, the inherited deletion in chromo-
some 11 from 41 Mb to 49 Mb had a consistent set of
values that did not change with fetal fraction. However,
the chromosome 15 duplication was clearly detected
between bins 27 and 66, albeit with more noise than
observed in the other artificial samples. The noise results
from the reduced apparent ff for this duplication due to
the mosaicism. The ffs calculated from the duplication
with z15j values were 1.6% and 3.0% for the 5% and 10%
mixtures, respectively. In contrast, the ffs calculated from170 The American Journal of Human Genetics 92, 167–176, Februarychromosome X with zXj were 5.3% and 10.7%. The
method was able to detect both the subchromosomal
duplication with the low mosaic ff and to distinguish
that the duplication was due to mosaicism by comparison
of the ff result to an independent measurement of chromo-
some X.
Duplications of Chromosome 22
Family 1925 consisted of a mother and two male
twins, one of which had two duplications of different
sizes in chromosome 22. 10% mixtures of the affected
twin’s DNA and the mother were sequenced. The results
indicated a 2 Mb and an 8 Mb duplication at bins
17 and 43, respectively. The ff for 10% mixture was calcu-
lated to be 11.2% from the 2 Mb duplication, 11.6% from
the 8 Mb duplication, and 9.8% from chromosome X
(Figure S2).7, 2013
Figure 3. Maternal Plasma Sample
BE3096 zij 1 Mb Bin Results with a Fetal
Karyotype with a Duplication in Chromo-
some 6
Expanded regions show z6j 1 Mb bin
results. The figure shows a 38 Mb duplica-
tion, covering the region between 64 Mb
and 102 Mb of Chr 6.
Table 2. MPS Results on Maternal Plasma Samples that Are
Concordant with the Clinically Reported Karyotype
Sample
ID
Affected
Chr
Gain/
Loss
Start
Bin
End
Bin
Size
(Mb)
Chromosome
Region
BE3096 6 gain 64 102 38 6q12–6q16.3
7 gain 98.1 98.3 0.3 7q22.1
BF3404 7 loss 150.3 150.6 0.3 7q36.1
AK1604 8 loss 6 12 6 8p23.2–8p23.2
BE3236 15 loss 22 39 17 15q11.2–15q14
AF1019 17 gain 62 81 19 17q23.3–17q25.3
10 loss 134 135 2 10q26.3
BC2659 3 gain 158 198 40 3q25.32–3q29
X loss 1 10 9 Xp22.33–Xp22.31Maternal Plasma Samples
Whole-Chromosome Aneuploidy
Sample AL1893 was previously reported in the MELISSA
study as detected for trisomy 20.14 The 1 Mb bin deep se-
quencing results for this sample contain ~960 million
tags across the genome. The extra copy of chromosome
20 was clearly detected and the ff calculated from the 1
Mb bin data is 4.4%.
Duplications and Deletions
Sample BE3096 (Table 1) had a complex fetal karyotype
that involved the long arm of chromosome 6 (6q) and
two duplications, one of which was ~38 Mb in size. The
second duplication was reported as approximately 650
kb from the chromosome microarray analysis of cultured
villi. By using MPS we previously reported that this sample
showed an increased whole-chromosome normalized
chromosome value (NCV) in chromosome 6 (NCV ¼
3.6).14 This value was insufficient to classify this sample
as having a full-chromosome aneuploidy, but it was
consistent with the presence of a large duplication.
Figure 3 shows the 1 Mb bin results for this sample. All
the chromosomes other than chromosome 6 showed z
values that clustered around 0. By focusing only on
chromosome 6 (Figure 3), the exact region of the 38 Mb
duplication was identified. This 38 Mb corresponded to
the large duplication seen in the microarray karyotype,
and the ff calculated from this duplication was 11.9%.
The second duplication in the microarray karyotype
would not have been detected by our three-step criteria.
Improved analytic methodology and/or deeper se-
quencing should allow this duplication to be detected.
Finally, a 300 kb gain in chromosome 7 at 7q22.1 wasThe American Journal of Human Gealso identified by MPS in agreement
with the microarray results (Table 2).
Sample BF3404 came from a preg-
nant woman carrying a fetus with
a 7q36.1 deletion detected by meta-
phase karyotype analysis of chorionic
villi. Figure 4A shows the 1 Mb bin
results for this sample. Only chromo-
somes 7 and 8 showed 1Mb bins with
z values that met our criteria for
classification. Chromosome 7 showed
a single 1 Mb bin with a significant
decrease in the z value at 7q36.1 (de-
noted by blue circle in Figure 4A).
An examination of the data at higherresolution (100 kb bins) (Figure 4B) showed a deletion of
approximately 300 kb, which was consistent with the
karyotype report (Table 2). In this sample we also observed
an approximately 1 Mb deletion in both the 1 Mb and 100
kb bin data close to the centromere of chromosome 8
(Table 3 and denoted by the red circle in Figure 4). The
chromosome 8 deletion was not reported in the karyotype
obtained from chorionic villi (Table 1). The ffs calculated
from the chromosome 7 and 8 deletions were 18.4% and
68.5%, respectively. The ff calculated from chromosome
X was 2.8%. In this case, the high ff value for chromosome
8 indicated that this deletion, which was not reported in
the fetal metaphase karyotype, was maternal in origin. In
addition, the discordant value of the chromosome 7netics 92, 167–176, February 7, 2013 171
Figure 4. Maternal Plasma Sample
BF3404 zij 1 Mb Bin Results across the
Genome with a Fetal Karyotype with
a Deletion in Chromosome 7
This clinical sample has a karyotype with
a small deletion in chromosome 7 (blue
circle). Another small deletion is detected
in chromosome 8 (red circle). Expanded
regions show z7j and z8j 1 Mb and 100 kb
bin data. The figure shows a 1 Mb deletion
at bin number 150 Mb on Chr 7 (A). At
higher resolution (B), this deletion is found
to be 300 kb long, in the region from
150.3 Mb to 150.6 Mb of Chr 7. Note: the
putative copy-number gain seen in Chr 7
at bin number 156 in the 1 Mb data is not
seen in the same region in the 100 kb data.
The figure also shows a 2 Mb deletion on
Chr 8 (A) covering bins 46 Mb and 47 Mb.
At higher resolution (B), this resolves into
a 900 kb deletion, covering the region
from 46.9 Mb to 47.7 Mb of Chr 8.compared to chromosome X ff values suggests that part of
the signal could be due to themother. The karyotype report
indicated that the chromosome 7 ‘‘abnormality is most
likely a derivative from a carrier parent,’’ which is consis-
tent with the MPS data.
Sample AK1604 had a partial deletion of the short arm of
chromosome8.The1Mbbin results (FigureS3) indicatedan
approximately 6Mbdeletion in the p armof chromosome8
in agreementwith the karyotype (Table 2). The fetal fraction
calculated from this chromosome deletion was 8.4%.
Translocations
The fetal metaphase karyotype for sample BE3236 showed
an unbalanced translocation consisting of 45,XX,15,
der(21)t(15;21)(q15;p11.2). The 1 Mb bin results for this
sample are shown in Figure 5. There was a clear 17 Mb
deletion in chromosome 15 in agreement with the karyo-
type (Table 2). The ff calculated from the chromosome 15
deletion was 11.3%. No subchromosomal abnormalities
were detected in the chromosome 21 data to indicate the
translocation breakpoint.
Identification of Additional Material Not Identified by Karyotype
Two maternal samples had fetal karyotypes with added
material of unknown origin at specific chromosomes.172 The American Journal of Human Genetics 92, 167–176, February 7, 2013The 1 Mb bin results for sample
AF1019 are shown in Figure 6. From
the MPS data, the additional material
of unknown origin on the long arm of
chromosome 10 appeared to be
derived from an approximately 19
Mb duplication at the q terminus of
chromosome 17. There was also an
approximately 2 Mb deletion at the
q terminus of chromosome 10 that
was confirmed by the 100 kb bin
data. The ffs calculated from the chro-
mosome 17 duplication and chromo-some X (male fetus) were 12.5% and 9.4%, respectively.
The 2 Mb deletion on chromosome 10 had a calculated ff
of 19.4%. Finally, the MPS results for this sample indicated
a small (300 kb) duplication in chromosome 7 that was not
reported in the metaphase karyotype (Table 3).
The 1 Mb bin results for sample BC2659 are shown in
Figure S4. The karyotype for this sample indicated addi-
tional chromosomal material on the short arm of one of
the X chromosomes. The additional material of unknown
origin appeared to originate from a 40 Mb duplication at
the q terminus of chromosome 3. There was also an
approximately 9Mb deletion on the p arm of chromosome
X (Figure S4) although the signal from this deletion did not
meet our criteria for classifying it as a CNV. The ffs calcu-
lated from the chromosome 3 duplication and chromo-
some X deletion were 9.5% and 6.7%, respectively. The
MPS results for this sample also indicated three small sub-
chromosomal changes that were not reported in the meta-
phase karyotype (Table 3).
Mosaic Karyotypes
Four of the samples listed in Table 1 (AL1873, BE3129,
BG3701, AH1200) had mosaic karyotypes with subchro-
mosomal abnormalities. Unfortunately, for three of the
Table 3. Copy-Number Variants Detected by MPS that Were Not
Reported in the Clinical Karyotypes
Sample
ID
Affected
Chr
Gain or
Loss
Start
Bin
End
Bin
Size
(Mb)
Chromosome
Region
AL1893 2 gain 87.3 87.9 0.6 2p11.2
2 loss 89.8 90.2 0.5 2p11.2
BF3404 8 loss 46.9 47.7 0.9 8q11.1
AF1019 7 gain 158.7 158.9 0.3 7q36.3
BC2659 3 loss 114 114.5 0.6 3q13.31
11 loss 55.3 55.4 0.2 11q11
17 gain 81 81.1 0.2 17q25.3
AL1873 1 loss 12.8 13 0.3 1p36.21
BE3129 7 loss 39.3 40 0.8 7p14.1
14 loss 58 58.1 0.2 14q23.1
BG3701 9 gain 40.7 41 0.4 9p31.1
AH1200 6 loss 151.4 151.5 0.2 6q25.1
22 gain 25.6 25.9 0.4 22q11.23samples (AL1873, BG3701, AH1200) the putative subchro-
mosomal abnormality originates in regions of the genome
for which information is either unavailable in the genome
build or highly repetitive and not accessible for analysis.
Thus, we were unable to determine the subchromosomal
abnormalities reported in these three samples. The zij
values for these samples were all close to and centered
around zero. Sample BE3129 had a mosaic karyotype
with isochromosome 20q, an abnormality that is reported
to be associated with an event secondary to postzygotic
error.18 Because cfDNA primarily originates from placental
cytotrophoblasts, it is not expected that this abnormality
would be detected with MPS. There were 1–2 small sub-The Americchromosomal changes detected in these samples by MPS
that were not reported in the karyotypes (Table 3).Discussion
This study demonstrates that in nonmosaic cases, it is
possible to obtain a fetal molecular karyotype that is equiv-
alent to CMA by MPS of maternal plasma cfDNA. In some
cases the MPS results provided better resolution than
a metaphase karyotype obtained from chorionic villi or
amniocytes. Such a noninvasive test could have clinical
utility in the near future, particularly for women who
either have a medical contraindication or lack of access
to an invasive procedure.
With 25-mer tags at ~109 tags/sample, the results shown
here indicate that sufficient precision can be obtained
between sequencing runs to reliably achieve 100 kb resolu-
tion across the genome. Even greater resolution can be
achieved with deeper sequencing. The improvements in
the Illumina v3 sequencing chemistry allowed for the use
of 25-mer tags, compared to the 36-mers used in our
previous work.14 These short tags mapped with high effi-
ciency across the genome, and the quantitative behavior
demonstrated with the artificial mixture analyses validates
the methodology. Today, the current cost of sequencing
a human genome with 30–603 coverage via paired-end
sequencing of 75–100 bp from each end is ~$5,000.
However, with the single-ended 25-mer reads utilized
here, one billion tags can be obtained for less than
$1,000 per sample. This is comparable to the cost of
a CMA but employs a risk-free blood draw rather than an
invasive procedure. Deeper sequencing would allow for
even finer resolution at an additional cost. Thus, this
type of analysis could be implemented as a reflex test
when other clinical factors are present (such asFigure 5. Maternal Plasma Sample
BE3236 zij 1 Mb Bin Results across the
Genome for Clinical Sample with a Fetal
Karyotype with an Unbalanced Transloca-
tion Involving Chromosome 15
Expanded region shows z15j 1 Mb bin
data. The figure shows a 17 Mb deletion
in the region between 22 Mb and 39 Mb
of Chr 15.
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Figure 6. Maternal Plasma Sample
AF1019 zij 1 Mb Bin Results across the
Genome with Additional Unspecified
Material in the Fetal Karyotype
Expanded regions show z10j and z17j 1 Mb
bin data. The figures show a 19 Mb
duplication of the region from 62 Mb to
81 Mb on Chr 17 and a 2 Mb deletion on
Chr 10 from 134 Mb to 135 Mb.sonographically detected anomalies that are not typical of
whole-chromosome aneuploidy) and the pregnant woman
declines an invasive procedure or prefers a blood test.
The lack of results on the mosaic samples (except for the
artificial mixture) highlights the current limitations of
both the microarray and MPS approaches. Subchromoso-
mal abnormalities that originate in regions of the genome
for which information is either unavailable in the genome
build or highly repetitive will not be accessible for analysis.
Such inaccessible genome regions are typically focused in
the telomeres and centromeres of different chromosomes
and in the short arms of acrocentric chromosomes. Also,
balanced translocations are a challenge for both the CMA
and MPS methods although MPS may be able to detect
translocation junctions with deeper sequencing. Finally,
the mosaic portion of a sample may be more challenging
for detection because of its lower effective ff. This may
require even deeper sequencing for effective classification.
Metaphase cytogenetic analysis from cell cultures,
although considered ‘‘standard,’’ has some limitations
that need to be considered. For example, the ability to
detect subchromosomal abnormalities is typically limited
to sizes of 5 Mb or greater. This constraint is what led to
the recent recommendation of using CMAs as a first tier
test in clinical practice. Cell culture is biased toward the
detection of more stable chromosomal configurations
over significant structural alterations. In the case of fluores-
cence in situ hybridization (FISH), only the regions of the
genome that are addressed by design of the FISH probes
can be analyzed. Finally, as shown here, in actual clinical
practice metaphase karyotypes can be reported to contain
‘‘chromosomal material of unknown origin.’’ The MPS
methodology of measuring copy-number variation intro-
duced in this work overcomes these limitations of karyo-
typing.174 The American Journal of Human Genetics 92, 167–176, February 7, 2013Importantly, our results showed
that MPS was able to identify the
potential source of the material of
unknown origin for clinical samples
AF1019 and BC2659. In addition,
the MPS data showed small deletions
in the termini of the chromosomes
that the metaphase karyotype indi-
cated were the breakpoints for the
unknown chromosomal material in
each of these samples. Such deletions
at the breakpoints of translocationshave been reported repeatedly in the literature.19 Based
on these results, MPS may have the capabilities to both
identify the presence of a subchromosomal duplication
and suggest a translocation position based on small dele-
tions (or duplications) elsewhere in the genome. More
data on translocations will need to be collected to further
validate translocation classifications.
Two recent papers have utilized even deeper sequenc-
ing than used here to identify fetal single-nucleotide
polymorphisms and haplotypes from maternal plasma
samples.20,21 Although this work suggests an exciting
future path toward routine noninvasive detection of the
entire fetal genome, most clinicians are not yet ready to
interpret the massive amounts of information that will
come from the entire sequence. They are, however, already
familiar with CMAs, so our work can potentially be trans-
lated to clinical care more expeditiously and eventually
provide a rationale for whole-genome sequencing of the
fetus.
The methodologies developed here also have applica-
tions beyond the determination of fetal subchromosomal
abnormalities from cfDNA inmaternal plasma. Ultimately,
MPS can be applied to any mixed biological sample in
which one wishes to determine the subchromosomal
abnormalities in the minor component, even when the
minor component represents only a few percent of the
total DNA in the specimen. In prenatal diagnostics,
samples obtained from chorionic villi could be analyzed
for mosaic karyotypes or maternal contamination.
Outside of prenatal diagnosis, many different cancers
have been associated with copy-number changes that
could potentially be detected from cfDNA in the blood of
an individual or a solid tumor sample that contains
both normal and cancer cells. As the cost of MPS continues
to drop, we expect that its application for detecting
subchromosomal abnormalities in mixed samples will find
broad clinical utility.
In summary, determination of fetal subchromosome
abnormalities via deep sequencing of maternal plasma
allows for a molecular karyotype of the fetus to be deter-
mined noninvasively. Such a test could be available in
the near future at a cost comparable to an invasive proce-
dure but without the associated procedural risks.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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